Myriad Genetics Q1 2026 Earnings EPS Miss Highlights Continued Operational Challenges CTOS Q1 2026 Earnings EPS Surprises with Smaller Loss but Stock Dips Progress Software PRGS Q1 2026 Earnings Narrow EPS Beat Drives Modest Share Gains Lisata Therapeutics Q3 2025 Earnings NarrowerthanExpected Loss as Biotech Advances Clinical Pipeline ENVB Q4 2024 Earnings Deep EPS Miss and Continued PreRevenue Stage Pressure ProQR Therapeutics Q1 2026 Earnings Narrower Net Loss No Revenue as Pipeline Progress Drives Stock Gains